Free Trial Information
BioCentury | Jul 22, 2013
Company News

AmorChem L.P., Institut national de la recherche scientifique deal

...Life science VC fund AmorChem invested an undisclosed amount to validate two urotensin II receptor modulators discovered at...
Read More
BioCentury | Feb 13, 2012
Clinical News

SAR101099: Development discontinued

...Details were not disclosed. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: SAR101099 Business: Renal Molecular target: Urotensin II receptor...
Read More
BioCentury | Nov 15, 2010
Clinical News

SAR101099: Phase I started

...treat diabetic nephropathy. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: SAR101099 Business: Renal Molecular target: Urotensin II receptor...
Read More
BioCentury | Jun 26, 2006
Finance

Actelion chronicles

...palosuran for diabetic nephropathy after preliminary Phase II data did not show efficacy for the urotensin II receptor...
Read More
BioCentury | May 30, 2005
Finance

Ebb & Flow

...after preliminary data did not show efficacy as measured by markers of kidney function. The urotensin II receptor...
Read More
BioCentury | May 30, 2005
Clinical News

Palosuran: Development discontinued

ATLN discontinued development of palosuran after preliminary data did not show efficacy as measured by markers of kidney function. The urotensin-II receptor antagonist was in 3 Phase II trials in about 100 patients. There were...
Read More
BioCentury | May 24, 2005
Clinical News

Actelion discontinues palosuran

...after preliminary data did not show efficacy as measured by markers of kidney function. The urotensin II receptor...
Read More
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
Read More
BioCentury | Nov 3, 2003
Clinical News

ACT-058362: Phase IIa

...IIa trials this month. Actelion Ltd. (SWX:ATLN), Allschwil, Switzerland Product: ACT-058362 Business: Renal Molecular target: Urotensin-II (UT-II) receptor...
Read More
BioCentury | Nov 3, 2003
Clinical News

ACT-058362: Phase I

...support twice- daily dosing. Actelion Ltd. (SWX:ATLN), Allschwil, Switzerland Product: ACT-058362 Business: Renal Molecular target: Urotensin-II (UT-II) receptor...
Read More
Items per page:
1 - 10 of 13